TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25637266

Group type: EXPERIMENTAL
Intervention: Edivoxetine (EDX) 6 mg or 9 mg once daily for 14 or 15 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 80 mg once daily for 14 or 15 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24102571

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg kg(‐1) over 10 minutes, followed by 0.4 μg kg(‐1)h(‐1) for 60 minutes)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 35
Study: 22097636

Group type: EXPERIMENTAL
Intervention: Pitch-only condition
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dual-axis condition (pitch and roll)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Triple-axis condition (pitch, roll, and yaw)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (pitch-only)
Number of subjects: 61
Study: 19332208

Group type: EXPERIMENTAL
Intervention: Average inhospital glucose levels (mean of glucose levels at admission, 6 hours, and 24 hours)
Number of subjects: 30536

Group type: EXPERIMENTAL
Intervention: Diabetes history
Number of subjects: 30536

Group type: EXPERIMENTAL
Intervention: Average glucose > or =144 mg/dL (8 mmol/L)
Number of subjects: 30536

Group type: COMPARATOR
Intervention: Diabetes history alone
Number of subjects: 30536

Group type: COMPARATOR
Intervention: Average glucose alone
Number of subjects: 30536

Group type: COMPARATOR
Intervention: Glucose plus diabetes history
Number of subjects: 30536
Study: 21797816

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rimonabant 40 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rimonabant (20 or 40 mg)
Number of subjects: 14
Study: 15951652

Group type: EXPERIMENTAL
Intervention: Radiofrequency facet joint denervation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 81
Study: 12730412

Group type: EXPERIMENTAL
Intervention: Betaine (6 g daily for 6 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Folic acid (800 micro g daily for 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (6 g daily for 6 weeks)
Number of subjects: 36
Study: 10473149

Group type: EXPERIMENTAL
Intervention: Five-position grip strength test (5PGST)
Number of subjects: 30
Study: 8847950

Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid mixture (31.5 grams)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 6
Study: 2285608

Group type: EXPERIMENTAL
Intervention: Combination therapy using Flutamide and LHRH agonist (or orchiectomy) for an average of 771 days (24‐2607 days)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Combination therapy using Flutamide and LHRH agonist (or orchiectomy)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Monotherapy (not specified in detail)
Number of subjects: 363
Study: 393731

Group type: EXPERIMENTAL
Intervention: 0.5 mg nickel supplements given on Monday and Tuesday of each week for at least 1 month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dietary restriction of nickel
Number of subjects: 10
Study: 28531302

Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation (Contingent, n = 143)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control condition (Noncontingent, n = 110)
Number of subjects: 253
Study: 28166816

Group type: EXPERIMENTAL
Intervention: ACHRU-CPP program (6-month interprofessional, nurse-led program)
Number of subjects: 160
Study: 26063161

Group type: EXPERIMENTAL
Intervention: mHealth+CP (n=166)
Number of subjects: 331

Group type: COMPARATOR
Intervention: standard mHealth (n=165)
Number of subjects: 331
Study: 23905242

Group type: EXPERIMENTAL
Intervention: Modified group: preoperative intramuscular injection of 50 mg dolantin, venous injection of 2 ml physiological saline, 10 mg dexamethasone, 5 mg ephedrine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Traditional group: intramuscular injection of 10 mg diazepam prior to routine anesthesia
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Modified group
Number of subjects: 118

Group type: COMPARATOR
Intervention: Traditional group
Number of subjects: 118
Study: 21084068

Group type: EXPERIMENTAL
Intervention: Safer environmental interventions (nuisance party enforcement, minor decoy operations, DUI checkpoints, social host ordinances, media visibility)
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: Safer environmental interventions
Number of subjects: 14000
Study: 18758699

Group type: EXPERIMENTAL
Intervention: Nebivolol (starting dose 2.5 mg once daily for 6 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Metoprolol (starting dose 25 mg once daily for 6 weeks)
Number of subjects: 39
Study: 16644608

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 50

Group type: COMPARATOR
Intervention: timolol-latanoprost combination
Number of subjects: 50
Study: 12588678

Group type: EXPERIMENTAL
Intervention: Spend Less. Eat Well. Feel Better. (SLEWFB) program
Number of subjects: 95

Group type: COMPARATOR
Intervention: 1-hour food safety intervention
Number of subjects: 95
Study: 11114263

Group type: EXPERIMENTAL
Intervention: Ataxia-telangiectasia (AT) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Charcot-Marie-Tooth 1A (CMT-1A) patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurotoxin-induced motor discoordination model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetic neuropathy model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hereditary cerebellar ataxia model
Number of subjects: 0
Study: 8651712

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 122
Study: 1510736

Group type: EXPERIMENTAL
Intervention: Group I (9 kV/m, 20 microT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group II (9 kV/m, 20 microT)
Number of subjects: 30
Study: 6192155

Group type: EXPERIMENTAL
Intervention: gingivectomy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: flap‐excision
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: gingivectomy and flap‐excision
Number of subjects: 6
Study: 29866467

Group type: EXPERIMENTAL
Intervention: Combination treatment (solifenacin succinate 5mg plus mirabegron 50mg)
Number of subjects: 1794

Group type: COMPARATOR
Intervention: Mirabegron 50mg
Number of subjects: 1794

Group type: COMPARATOR
Intervention: Solifenacin 5mg
Number of subjects: 1794
Study: 27227679

Group type: EXPERIMENTAL
Intervention: PrePex device
Number of subjects: 240

Group type: COMPARATOR
Intervention: Forceps-guided surgical circumcision
Number of subjects: 240
Study: 24848282

Group type: EXPERIMENTAL
Intervention: Patients with RA and proteinuria
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy blood donors)
Number of subjects: 42

Group type: COMPARATOR
Intervention: RA patients without proteinuria
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with glomerulonephritis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with AA-amyloidosis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with tubulointerstitial nephritis
Number of subjects: 42
Study: 22891946

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-IV (apoA-IV) concentration
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-IV (apoA-IV) concentration in patients with BMI > 23 kg m(‐2)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-IV (apoA-IV) concentration in nonwasting group
Number of subjects: 1255
Study: 20164553

Group type: EXPERIMENTAL
Intervention: Radiofrequency field exposure (890-MHz GSM signal, specific absorption rate of 1.0 Watt/kg) for 30 minutes
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Use of oral snuff
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Time since first use of mobile phones and desktop cordless phones combined
Number of subjects: 313
Study: 17662037

Group type: EXPERIMENTAL
Intervention: Active immunotherapy with Alternaria alternata extract
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16209678

Group type: EXPERIMENTAL
Intervention: Lubricated endoscope
Number of subjects: 150

Group type: COMPARATOR
Intervention: Unlubricated endoscope
Number of subjects: 150
Study: 15189613

Group type: EXPERIMENTAL
Intervention: Imagining oneself in the other's place
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagining the other's feelings
Number of subjects: 0
Study: 11868841

Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice containing 0.3% triclosan, 2.0% PVM/MA copolymer, and 0.243% sodium fluoride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride
Number of subjects: 0
Study: 10561949

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg plus dexamethasone 8 mg i.v. on day 1 followed by tropisetron 5 mg p.o. plus dexamethasone 4 mg orally bid on day 2‐6 (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tropisetron 5 mg p.o. alone on day 2‐6 (group II)
Number of subjects: 30
Study: 8778152

Group type: EXPERIMENTAL
Intervention: plain Synacthen, 250 micrograms, iv
Number of subjects: 20

Group type: COMPARATOR
Intervention: depot Synacthen, 1000 micrograms, im
Number of subjects: 20
Study: 2225517

Group type: EXPERIMENTAL
Intervention: Electrode A (gastric antrum)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electrode B (gastric body)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aspiration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both electrodes
Number of subjects: 5
Study: 7461012

Group type: EXPERIMENTAL
Intervention: Tiamenidine (HOE 440)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (after withdrawal of Tiamenidine)
Number of subjects: 10
Study: 31744796

Group type: EXPERIMENTAL
Intervention: Cord blood serum (CBS) eyedrops administered eight times/day for 1 month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Peripheral adult donor blood serum (PBS) eyedrops administered eight times/day for 1 month
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CBS treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: PBS treatment
Number of subjects: 60
Study: 31154814

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies and small interventional studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic recommendations
Number of subjects: 0
Study: 28593244

Group type: EXPERIMENTAL
Intervention: Mandarin orange yogurt for 2 weeks
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mandarin orange yogurt
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control yogurt (lacking mandarin orange)
Number of subjects: 57
Study: 26001320

Group type: EXPERIMENTAL
Intervention: Endovascular (EVAR)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Open Surgical Repair (OSR)
Number of subjects: 107
Study: 24219189

Group type: EXPERIMENTAL
Intervention: Motor learning program (goal-oriented stepping and walking, strength training, twice weekly for 1 hour for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard exercise program (endurance training by treadmill walking, strength training, twice weekly for 1 hour for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (Motor learning and Standard)
Number of subjects: 40
Study: 21209239

Group type: EXPERIMENTAL
Intervention: Fostamatinib (R788) 100 mg orally, twice daily from days 4 to 8 and once daily on days 3 and 9.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo, twice daily from days 4 to 8 and once daily on days 3 and 9.
Number of subjects: 16
Study: 19064372

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy
Number of subjects: 3670

Group type: EXPERIMENTAL
Intervention: Cognitive depression
Number of subjects: 3670

Group type: EXPERIMENTAL
Intervention: Symptom intrusiveness
Number of subjects: 3670
Study: 17598695

Group type: EXPERIMENTAL
Intervention: Dexamethasone dihydrogen phosphate disodium salt (test product)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Comparator product (control)
Number of subjects: 210
Study: 15039645

Group type: EXPERIMENTAL
Intervention: Conventional laparoscopy under GA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy under GA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy under epidural anesthesia
Number of subjects: 24
Study: 11533360

Group type: EXPERIMENTAL
Intervention: Intensive home visiting program
Number of subjects: 225
Study: 9462459

Group type: EXPERIMENTAL
Intervention: Selective attention to grating orientation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task involving selective attention to grating dimensions
Number of subjects: 0
Study: 7939398

Group type: EXPERIMENTAL
Intervention: Cisapride (5 mg four times daily)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Cimetidine (200 mg four times daily)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 137

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 137
Study: 2896104

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 4.4 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29254749

Group type: EXPERIMENTAL
Intervention: Water intake (GII)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Oral rehydrating fluids (GIII)
Number of subjects: 325

Group type: COMPARATOR
Intervention: No fluid intake (GI)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Comparison between GII and GIII
Number of subjects: 325
Study: 26866954

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) or emtricitabine/TDF
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 24366750

Group type: EXPERIMENTAL
Intervention: 75 mg oseltamivir
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both doses of oseltamivir (75 mg and 150 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Standard dosing of oseltamivir
Number of subjects: 24
Study: 22790902

Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring worn for 12 weeks
Number of subjects: 170
Study: 20660039

Group type: EXPERIMENTAL
Intervention: Postoperative TSH suppression therapy (group A) with L-T(4) to keep serum TSH levels below 0.01 μU/ml
Number of subjects: 433

Group type: COMPARATOR
Intervention: No TSH suppression (group B) with TSH levels adjusted to within normal ranges
Number of subjects: 433
Study: 18771362

Group type: EXPERIMENTAL
Intervention: Autogenous bone grafting plus calcium sulfate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Autogenous bone grafting with a bioabsorbable membrane
Number of subjects: 12
Study: 16199249

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg/d for 5 days
Number of subjects: 177

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg/d for 10 days
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 177
Study: 15032259

Group type: EXPERIMENTAL
Intervention: 150 mg bupropion SR daily and PTC
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: 150 mg bupropion SR daily and TM
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: 300 mg bupropion SR daily and PTC
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: 300 mg bupropion SR daily and TM
Number of subjects: 1524

Group type: COMPARATOR
Intervention: 150 mg bupropion SR
Number of subjects: 1524

Group type: COMPARATOR
Intervention: 300 mg bupropion SR
Number of subjects: 1524
Study: 11054442

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g every 8 hours)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Ceftazidime (2 g every 8 hours)
Number of subjects: 411
Study: 8818068

Group type: EXPERIMENTAL
Intervention: CATCH family intervention with varying levels of adult participation (measured by the number of activity packets completed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CATCH family intervention
Number of subjects: 0
Study: 1577054

Group type: EXPERIMENTAL
Intervention: DuP-753 25 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DuP-753 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DuP-753 100 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DuP-753 200 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DuP-753 100 mg (multiple doses)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3900800

Group type: EXPERIMENTAL
Intervention: Iotrol
Number of subjects: 100

Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 100

Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 100
Study: 3301683

Group type: EXPERIMENTAL
Intervention: High doses of anti-lipid A
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 17
Study: 30172572

Group type: EXPERIMENTAL
Intervention: Technology-enabled nurse coaching intervention
Number of subjects: 132
Study: 29871286

Group type: EXPERIMENTAL
Intervention: Modified tympanic membrane surgical knife with suction and tube device
Number of subjects: 87

Group type: COMPARATOR
Intervention: General approach for tympanic membrane tube insertion
Number of subjects: 87
Study: 26172395

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1800 mg orally for 4 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 23238789

Group type: EXPERIMENTAL
Intervention: FREMS
Number of subjects: 110
Study: 21944176

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 200
Study: 18721823

Group type: EXPERIMENTAL
Intervention: Chocolate-flavored dairy drink
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chocolate-flavored dairy semi-solid
Number of subjects: 2
Study: 16846541

Group type: EXPERIMENTAL
Intervention: Budesonide HFA pMDI 200 mug twice daily
Number of subjects: 159

Group type: COMPARATOR
Intervention: Budesonide CFC pMDI 200 mug twice daily
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both budesonide formulations (HFA and CFC)
Number of subjects: 159
Study: 11870012

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 10465472

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (XRT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Endobronchial treatment (brachytherapy, laser resection, or cryotherapy)
Number of subjects: 75
Study: 7840053

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of epoprostenol plus conventional therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 33
Study: 2369312

Group type: EXPERIMENTAL
Intervention: Limited incision (muscle-sparing thoracotomy)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard thoracotomy
Number of subjects: 28
Study: 627191

Group type: EXPERIMENTAL
Intervention: Rheomacrodex 10%
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (physiological saline)
Number of subjects: 54
Study: 29679844

Group type: EXPERIMENTAL
Intervention: Impairment Rating Scale‐ADHD
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard Impairment Rating Scale
Number of subjects: 107
Study: 26395438

Group type: EXPERIMENTAL
Intervention: Minimally supervised exercise program
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 231
Study: 24838056

Group type: EXPERIMENTAL
Intervention: Mid-septal lead position
Number of subjects: 299

Group type: COMPARATOR
Intervention: Apical lead position
Number of subjects: 299
Study: 22624834

Group type: EXPERIMENTAL
Intervention: J-wave in patients with idiopathic VF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pause-dependent augmentation of J waves during storms of VF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pause-dependent augmentation of J waves after sudden R-R prolongation
Number of subjects: 40

Group type: COMPARATOR
Intervention: J waves in control subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pause-dependent augmentation of J waves
Number of subjects: 40
Study: 21491007

Group type: EXPERIMENTAL
Intervention: Transbond Moisture Insensitive Primer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional Transbond XT primer
Number of subjects: 45
Study: 18524974

Group type: EXPERIMENTAL
Intervention: Iodixanol-270 (60 mL intravenous bolus)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no iodinated contrast media)
Number of subjects: 100
Study: 16632399

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) with radiation therapy (RT) - mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), cyclophosphamide (500 mg/m2), 6 cycles, first 3 cycles of CT with RT
Number of subjects: 214

Group type: COMPARATOR
Intervention: Sequential chemotherapy (CT) followed by radiation therapy (RT) - mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), cyclophosphamide (500 mg/m2), 6 cycles, RT started 3 to 5 weeks after the 6th cycle of CT
Number of subjects: 214
Study: 14653835

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lafutidine 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water only (baseline data)
Number of subjects: 18
Study: 10228604

Group type: EXPERIMENTAL
Intervention: Echinaforce (Echinacea purpurea-preparation from 95% herba and 5% radix)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea concentrate (7 times higher concentration)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Special Echinacea purpurea radix preparation
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 8904594

Group type: EXPERIMENTAL
Intervention: Nasal inhalation of cold dry air (‐4 degrees C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal inhalation of cold dry air (‐10 degrees C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal inhalation of dry air (0.3% RH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal inhalation of moist room air (97% RH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral breathing of cold dry air, dry air, or moist air
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal anesthesia or inhalation of a cholinergic antagonist before cold air
Number of subjects: 0